

107 mice in each group were challenged intranasally with 30 μ l of $10^{6.5}$ EID₅₀ of HK/1073/99 under
108 anesthesia. Mixture of tiletamine hydrochloride (20 mg/kg) (United States Pharmacopeia,
109 Maryland, U.S.A.), zolazepam hydrochloride (20 mg/kg) (United States Pharmacopeia), and
110 xylazine (20 mg/kg) (Bayer HealthCare, Osaka, Japan) was injected intraperitoneally into mice for
111 anesthesia.

112 Inactivated Dk/Hok/49/98 vaccines were also injected twice intraperitoneally into 4-week-old
113 female BALB/c mice. Two weeks later, the vaccine was again intraperitoneally injected into the
114 mice. One week after the second vaccination, 10 mice in each group were challenged intranasally
115 with 30 μ l of $10^{6.5}$ EID₅₀ of HK/1073/99 under anesthesia.

116 On day 3 post-infection, five mice in each group were sacrificed and the lungs were
117 homogenized to make a 10% (w/v) suspension with minimal essential medium (Nissui, Tokyo,
118 Japan) with antibiotics (penicillin G potassium, streptomycin sulfate, gentamicin sulfate, and
119 nystatin) and 0.5% Bovine Serum Albumin Fraction V (Roche, Basel, Switzerland). The virus
120 titers of the supernatants of the lung tissue homogenates were calculated in 10-day-old embryonated
121 chicken eggs and expressed as the EID₅₀/g of tissue.

122 In neutralization (NT) tests, titers were determined as the reciprocal of that maximum antibody
123 dilution that completely prevented cytopathic effect caused by 100 plaque forming units of virus
124 using MDCK cells.

125

126

127

128 **RESULTS**

129 *Phylogenetic analysis of the HA genes of H9N2 influenza viruses:* The HA genes of 22 H9N2
130 viruses were sequenced and phylogenetically analyzed by the neighbor-joining method. All of the

131 HA genes were classified into the Eurasian lineage, and further classified into the Korean (n=11),
132 Y280 (n=7), and G1 (n=4) sublineages (Fig. 1). The H9 viruses of the Korean and Y280
133 sublineages were isolated from water birds, poultry, pigs, and humans in east Asian countries, and
134 those of the G1 sublineage were isolated from poultry in west Asian countries (Fig. 1).

135 *Antigenicity of the H9N2 influenza viruses:* H9N2 influenza viruses were antigenically analyzed
136 by HI test (Table 2). Antisera against H9N2 viruses of the Y280 sublineage reacted slightly with
137 H9N2 viruses of the G1 and Korean sublineages. Antisera against H9N2 viruses of the G1
138 sublineage reacted more with H9N2 viruses of the Y280 sublineages than those of the Korean
139 sublineage. On the other hand, antisera against H9N2 viruses of the Korean sublineage reacted
140 with H9N2 viruses of all sublineages. This result suggested that the H9N2 vaccine strain should be
141 selected from the viruses of the Korean sublineage.

142 *Selection of H9N2 vaccine strain:* To select an H9N2 vaccine strain, four H9N2 viruses,
143 Dk/Hok/49/98, A/duck/Hokkaido/13/2000 (H9N2) (Dk/Hok/13/00), A/duck/Hokkaido/9/1999
144 (H9N2) (Dk/Hok/9/99), and A/duck/Hokkaido/26/1999 (H9N2) (Dk/Hok/26/99), were selected from
145 11 isolates of the Korean sublineage, and their replication and pathogenicity in embryonated chicken
146 eggs were assessed. HA titers of Dk/Hok/49/98, Dk/Hok/13/00, Dk/Hok/9/99, and Dk/Hok/26/99
147 were 512, 512, 256, and 128, respectively. Virus titers were $10^{9.7}$, $10^{8.3}$, $10^{8.3}$, and $10^{7.3}$ EID₅₀/ml,
148 respectively, indicating that Dk/Hok/49/98 replicated efficiently in 10-day-old embryonated chicken
149 eggs. Pathogenicity of Dk/Hok/49/98 in the embryonated chicken eggs was determined by mean
150 death time and that of Dk/Hok/49/98 was 91.8 h, indicating that Dk/Hok/49/98 had low
151 pathogenicity in chicken embryos. This virus was selected as a candidate H9N2 vaccine strain.

152 *Protective efficacy of the test vaccine in mice against H9N2 virus challenge:* To assess the
153 efficacy of the vaccine against H9N2 virus infection, HK/1073/99 was intranasally inoculated into
154 mice that had previously been vaccinated once with inactivated HK/1073/99 or Dk/Hok/49/98.

155 Immunogenicity of the inactivated vaccine was assessed by NT test, and virus titers in the lungs
156 were measured to assess protective immunity induced by the vaccine (Table 3). Serum antibodies
157 were detected in mice injected with 50, 10, and 2 μg protein of HK/1073/99 vaccine. The virus
158 titers in the lungs were $<10^{1.5}$ - $10^{3.7}$ EID₅₀/g in mice injected with 50 or 10 μg protein of HK/1073/99
159 vaccine, and $10^{4.7}$ - $10^{6.8}$ EID₅₀/g in the 2 and 0.4 μg vaccine groups, and in the PBS control group
160 (Table 3). A reduction in body weight was observed in mice injected with 10, 2, and 0.4 μg protein,
161 and in the control group from day 2 post-infection, reaching up to 10% body weight loss at days 3-4
162 post-infection, compared with in the mice that received 50 μg of protein (Fig. 2A).

163 We also tested the efficacy of vaccination with Dk/Hok/49/98 on protection against subsequent
164 intranasal infection with HK/1073/99. Serum antibodies were slightly detected in mice injected
165 with Dk/Hok/49/98 vaccine containing 50 and 10 μg protein (Table 3). The virus titers in the lungs
166 of mice injected with Dk/Hok/49/98 vaccine containing 50 and 10 μg protein were $10^{4.3}$ - $10^{5.3}$
167 EID₅₀/g. In the mice injected with 2 and 0.4 μg protein, the virus titers in the lungs of mice were
168 similar to those of non-vaccinated control mice (Table 3). Although, a reduction in body weight
169 was observed in mice at all doses of the Dk/Hok/49/98 vaccine, slight significant difference was
170 observed in mice injected with 50 μg protein, compared with in mice injected with PBS (Fig. 2B).

171 In the mice injected twice with Dk/Hok/49/98 vaccine on days 0 and 14, serum antibodies
172 were detected in mice in the 50, 10, and 2 μg groups at one week after the second injection (Table 4).
173 The virus titers in the lungs were $<10^{1.5}$ - $10^{3.8}$ EID₅₀/g in mice injected with 50, 10, and 2 μg protein,
174 and $10^{5.3}$ - $10^{6.5}$ EID₅₀/g in the other vaccinated mice (Table 4). A reduction in body weight was
175 observed in mice injected with 2 and 0.4 μg protein, and in control group, reaching up to 10%
176 weight loss from days 4-6 post-infection, compared with in mice injected with 50 and 10 μg protein
177 (Fig. 3). These results suggest that the repeat administration of the test vaccine confers immunity,
178 and prevents body weight loss and decreases virus replication, after infection of mice with H9

179 influenza virus.

180

181

182

183 **DISCUSSION**

184 H9N2 viruses of each of the three sublineages, G1, Y280, and Korean, were recently isolated
185 from wildbirds and poultry worldwide [3, 8, 27]. H9N2 viruses were also isolated from pigs and
186 humans in China [4-5, 37] and Korea, suggesting that these viruses have the potential to cause
187 pandemic influenza in humans. H9N2 viruses isolated from pigs in China and Korea were
188 classified into the Y280 and Korean sublineages, while H9N2 viruses isolated from humans in China
189 was classified into the G1 and Y280 sublineages [4-5, 23, 31]. It is suggested that H9N2 viruses
190 isolated from pigs and humans are antigenically distinct among viruses of the Korean, Y280, and G1
191 sublineages [5, 23, 31, 37]. Therefore, it is important that any H9N2 influenza virus vaccine to be
192 used for pandemic influenza can broadly cross-react with antisera against all sublineage viruses. In
193 the present study, Dk/Hok/49/98 was selected from the Korean sublineage, since antisera to the virus
194 cross-reacted with all sublineages virus. Furthermore, Dk/Hok/49/98 replicated efficiently in
195 embryonated chicken eggs and was non-pathogenic in chicken embryos. Recently, H9N2 viruses
196 were isolated from pigs and humans in China [4-5, 23, 31], it is necessary to analyze the antigenicity
197 of these H9 isolates and evaluate the efficacy of test vaccine against them. Taken together, it is
198 important to carry out surveillance of avian influenza consecutively and to analyze the isolates
199 antigenically and phylogenetically.

200 In the present study, it was suggested that the test whole particle vaccine has the potency
201 against challenge with H9N2 virus of different sublineage in mice. It was already reported that
202 whole particle vaccine induced strong immune responses and H5N1 whole particle vaccine induced

203 protective immunity against antigenically distinct challenge virus [12, 26]. Although the efficacy
204 of the test vaccine observed slightly in mice vaccinated once due to the antigenic difference between
205 Dk/Hok/49/98 and HK/1073/99, it was clear that the vaccine induced protective immunity in mice
206 injected twice, indicating the usefulness for the preparedness of the pandemic.

207 The current cycle of seasonal influenza vaccine production requires detailed planning up to 6
208 months before vaccine manufacture [7]. In the case of influenza pandemic in 2009, it also took 5
209 months to have an H1N1 vaccine available [6, 36]. To prepare for the emergence of pandemic
210 influenza in birds and mammals including humans, we have carried out global surveillance of avian
211 influenza [15, 30, 33, 39]. Avian influenza viruses of 144 combinations of HA and NA subtypes
212 have been stocked for use in vaccine and diagnosis. Since the viruses stocked in our influenza
213 virus library were already assessed the pathogenicity and replication in embryonated chicken eggs,
214 we can exclude those tests to select a vaccine strain and prepare a vaccine rapidly [16-17, 19]. The
215 present results indicate that the inactivated whole virus vaccine prepared from an influenza virus
216 from the library could be used as an emergency vaccine during the early stage of a pandemic caused
217 by H9N2 influenza virus infection.

218

219

220

221 **ACKNOWLEDGEMENTS**

222 We thank Dr. Ian Brown, Dr. Kennedy F. Shortridge, and Dr. Alan Hay for providing H9N2
223 influenza viruses. This study was supported by the Program of Founding Research Centers for
224 Emerging and Reemerging Infectious Diseases of Ministry of Education, Culture, Sports, Science
225 and Technology of Japan. This work was also supported by Japan Science and Technology Agency
226 Basic Research Programs.

227

228

229

230 **REFERENCES**

- 231 1. Abbas, M. A., Spackman, E., Swayne, D. E., Ahmed, Z., Sarmiento, L., Siddique, N., Naeem,
232 K., Hameed, A. and Rehmani, S. 2010. Sequence and phylogenetic analysis of H7N3 avian
233 influenza viruses isolated from poultry in Pakistan 1995-2004. *Virologica J.* **7**: 137.
- 234 2. Abenes, G. B., Okazaki, K., Fukushi, H., Kida, H., Honda, E., Yagyu, K., Tsuji, M., Sato,
235 H., Ono, E., Yanagawa, R. and Yamauchi, N. 1982. Isolation of ortho- and paramyxoviruses
236 from feral birds in Hokkaido, Japan--1980 and 1981. *J. Vet. Med. Sci.* **44**: 703-708.
- 237 3. Banet-Noach, C., Perk, S., Simanov, L., Grebenyuk, N., Rozenblut, E., Pokamunski, S.,
238 Pirak, M., Tendler, Y. and Panshin, A. 2007. H9N2 influenza viruses from Israeli poultry: a
239 five-year outbreak. *Avian Dis.* **51**: 290-296.
- 240 4. Butt, K. M., Smith, G. J., Chen, H., Zhang, L. J., Leung, Y. H., Xu, K. M., Lim, W.,
241 Webster, R. G., Yuen, K. Y., Peiris, J. S. and Guan, Y. 2005. Human infection with an avian
242 H9N2 influenza A virus in Hong Kong in 2003. *J. Clin. Microbiol.* **43**: 5760-5767.
- 243 5. Cheng, V. C., Chan, J. F., Wen, X., Wu, W. L., Que, T. L., Chen, H., Chan, K. H. and Yuen,
244 K. Y. 2011. Infection of immunocompromised patients by avian H9N2 influenza A virus. *J.*
245 *Infect.* **62**: 394-399.
- 246 6. Cirard, M. P., Tam, J. S., Assossou, O. M. and Kieny, M. P. 2010. The 2009 A (H1N1)
247 influenza virus pandemic: A review. *Vaccine* **28**: 4895-4902.
- 248 7. Gerdil, C. 2003. The annual production cycle for influenza vaccine. *Vaccine* **21**: 1776-1779.
- 249 8. Ge, F. F., Zhou, J. P., Liu, J., Wang, J., Zhang, W. Y., Sheng, L. P., Xu, F., Ju, H. B., Sun,
250 Q. Y. and Liu, P. H. 2009. Genetic evolution of H9 subtype influenza viruses from live

- 251 poultry markets in Shanghai, China. *J. Clin. Microbiol.* **47**: 3294-3300.
- 252 9. Guan, Y., Shortridge, K. F., Krauss, S. and Webster, R. G. 1999. Molecular characterization
253 of H9N2 influenza viruses: were they the donors of the "internal" genes of H5N1 viruses in
254 Hong Kong? *Proc. Natl. Acad. Sci. U.S.A.* **96**: 9363-9367.
- 255 10. Guan, Y., Shortridge, K. F., Krauss, S., Chin, P. S., Dyrting, K. C., Ellis, T. M., Webster, R.
256 G. and Peiris, M. 2000. H9N2 influenza viruses possessing H5N1-like internal genomes
257 continue to circulate in poultry in southeastern China. *J. Virol.* **74**: 9372-9380.
- 258 11. Guo, Y. J., Krauss, S., Senne, D. A., Mo, I. P., Lo, K. S., Xiong, X. P., Norwood, M.,
259 Shortridge, K. F., Webster, R. G. and Guan, Y. 2000. Characterization of the pathogenicity
260 of members of the newly established H9N2 influenza virus lineages in Asia. *Virology* **267**:
261 279-288.
- 262 12. Hagensars, N., Mastrobattista, E., Glansbeek, H., Heldens, J., van den Bosch, H., Schijns,
263 V., Betbeder, D., Vromans, H. and Jiskoot, W. 2008. Head-to-head comparison of four
264 nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition,
265 spatial organization and immunization route on the immunogenicity in a murine challenge
266 model. *Vaccine* **26**:6555-6563.
- 267 13. Haghighat-Jahromi, M., Asasi, K., Nili, H., Dadras, H. and Shooshtari, A. H. 2008.
268 Coinfection of avian influenza virus (H9N2 subtype) with infectious bronchitis live vaccine.
269 *Arch. Virol.* **153**: 651-655.
- 270 14. Hoffmann, E., Stechm, J., Guan, Y., Webster, R. G. and Perez, D. R. 2001. Universal
271 primer set for the full-length amplification of all influenza A viruses. *Arch. Virol.* **146**:
272 2275-2289.
- 273 15. Ito, T., Okazaki, K., Kawaoka, Y., Takada, A., Webster, R. G. and Kida, H. 1995.
274 Perpetuation of influenza A viruses in Alaskan waterfowl reservoirs. *Arch. Virol.* **140**:

- 275 1163-1172.
- 276 16. Itoh, Y., Ozaki, H., Ishigaki, H., Sakoda, Y., Nagata, T., Soda, K., Isoda, N., Miyake, T.,
277 Ishida, H., Okamoto, K., Nakayama, M., Tsuchiya, H., Torii, R., Kida, H. and Ogasawara,
278 K. 2010. Subcutaneous inoculation of a whole virus particle vaccine prepared from a
279 non-pathogenic virus library induces protective immunity against H7N7 highly pathogenic
280 avian influenza virus in cynomolgus macaques. *Vaccine* **28**: 780-789.
- 281 17. Itoh, Y., Ozaki, H., Tsuchiya, H., Okamoto, K., Torii, R., Sakoda, Y., Kawaoka, Y.,
282 Ogasawara, K. and Kida, H. 2008. A vaccine prepared from a non-pathogenic H5N1 avian
283 influenza virus strain confers protective immunity against highly pathogenic avian influenza
284 virus infection in cynomolgus macaques. *Vaccine* **26**: 562-572.
- 285 18. Jeong, O. M., Kim, Y. J., Choi, J. G., Kang, H. M., Kim, M. C., Kwon, J. H. and Lee, Y. J.
286 2011. Genetic characterization of H1 avian influenza viruses isolated from migratory birds
287 and domestic ducks in Korea. *Virus Genes* **42**: 55-63.
- 288 19. Kida, H. and Sakoda, Y. 2006. Library of influenza virus strains for vaccine and diagnostic
289 use against highly pathogenic avian influenza and human pandemics. *Dev. Biol. (Basel)*
290 **124**: 69-72.
- 291 20. Kida, H. and Yanagawa, R. 1979. Isolation and characterization of influenza A viruses from
292 wild free-flying ducks in Hokkaido, Japan. *Zentralbl. Bakteriol. Orig. A* **244**: 135-143.
- 293 21. Kim, H. R., Lee, Y. J., Lee, K. K., Oem, J. K., Kim, S. H., Lee, M. H., Lee, O. S. and Park,
294 C. K. 2010. Genetic relatedness of H6 subtype avian influenza viruses isolated from wild
295 birds and domestic ducks in Korea and their pathogenicity in animals. *J. Gen. Virol.* **91**:
296 208-219.
- 297 22. Kishida, N., Sakoda, Y., Eto, M., Sunaga, Y. and Kida, H. 2004. Co-infection of
298 *Staphylococcus aureus* or *Haemophilus paragallinarum* exacerbates H9N2 influenza A virus

- 299 infection in chickens. *Arch. Virol.* **149**: 2095-2104.
- 300 23. Lin, Y. P., Shaw, M., Gregory, V., Cameron, K., Lim, W., Klimov, A., Subbarao, K., Guan,
301 Y., Krauss, S., Shortridge, K., Webster, R., Cox, N. and Hay, A. 2000. Avian-to-human
302 transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1
303 human isolates. *Proc. Natl. Acad. Sci. U.S.A.* **97**: 9654-9658.
- 304 24. Liu, J., Okazaki, K., Ozaki, H., Sakoda, Y., Wu, Q., Chen, F. and Kida, H. 2003. H9N2
305 influenza viruses prevalent in poultry in China are phylogenetically distinct from
306 A/quail/Hong Kong/G1/97 presumed to be the donor of the internal protein genes of the
307 H5N1 Hong Kong/97 virus. *Avian Pathol.* **32**: 551-560.
- 308 25. Liu, J. H., Okazaki, K., Shi, W. M., Wu, Q. M., Mweene, A. S. and Kida, H. 2003.
309 Phylogenetic analysis of neuraminidase gene of H9N2 influenza viruses prevalent in
310 chickens in China during 1995-2002. *Virus Genes* **27**: 197-202.
- 311 26. Lu, X., Edwards, L. E., Desheva, J. A., Nguyen, D. C., Rekstin, A., Stephenson, I., Szretter,
312 K., Cox, N. J., Rudenko, L. G., Klimov, A. and Katz, J. M. 2006. Cross-protective
313 immunity in mice induced by live-attenuated or inactivated vaccines against highly
314 pathogenic influenza A (H5N1) viruses. *Vaccine* **24**: 6588-6593.
- 315 27. Nagarajan, S., Rajukumar, K., Tosh, C., Ramaswamy, V., Purohit, K., Saxena, G., Behera,
316 P., Pattnaik, B., Pradhan, H. K. and Dubey, S. C. 2009. Isolation and pathotyping of H9N2
317 avian influenza viruses in Indian poultry. *Vet. Microbiol.* **133**: 154-163.
- 318 28. Ninomiya, A., Imai, M., Tashiro, M. and Odagiri, T. 2007. Inactivated influenza H5N1
319 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous
320 protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza
321 viruses in a mouse model. *Vaccine* **25**: 3554-3360.
- 322 29. Nguyen, D. C., Uyeki, T. M., Jadhao, S., Maines, T., Shaw, M., Matsuoka, Y., Smith, C.,

- 323 Rowe, T., Lu, X., Hall, H., Xu, X., Balish, A., Klimov, A., Tumpey, T. M., Swayne, D. E.,
324 Huynh, L. P., Nghiem, H. K., Nguyen, H. H., Hoang, L. T., Cox, N. J. and Katz, J. M. 2005.
325 Isolation and characterization of avian influenza viruses, including highly pathogenic H5N1,
326 from poultry in live bird markets in Hanoi, Vietnam, in 2001. *J. Virol.* **79**: 4201-4212.
- 327 30. Okazaki, K., Takada, A., Ito, T., Imai, M., Takakuwa, H., Hatta, M., Ozaki, H., Tanizaki, T.,
328 Nagano, T., Ninomiya, A., Demenev, V. A., Tyaptirganov, M. M., Karatayeva, T. D.,
329 Yamnikova, S. S., Lvov, D. K. and Kida, H. 2000. Precursor genes of future pandemic
330 influenza viruses are perpetuated in ducks nesting in Siberia. *Arch. Virol.* **145**: 885-893.
- 331 31. Peiris, M., Yuen, K. Y., Leung, C. W., Chan, K. H., Ip, P. L., Lai, R. W., Orr, W. K. and
332 Shortridge, K. F. 1999. Human infection with influenza H9N2. *Lancet* **354**: 916-917.
- 333 32. Perez, D. R., Lim, W., Seiler, J. P., Yi, G., Peiris, M., Shortridge, K. F. and Webster, R. G.
334 2003. Role of quail in the interspecies transmission of H9 influenza A viruses: molecular
335 changes on HA that correspond to adaptation from ducks to chickens. *J. Virol.* **77**:
336 3148-3156.
- 337 33. Sakoda, Y., Sugar, S., Batchluun, D., Erdene-Ochir, T. O., Okamatsu, M., Isoda, N., Soda,
338 K., Takakuwa, H., Tsuda, Y., Yamamoto, N., Kishida, N., Matsuno, K., Nakayama, E.,
339 Kajihara, M., Yokoyama, A., Takada, A., Sodnomdarjaa, R. and Kida, H. 2010.
340 Characterization of H5N1 highly pathogenic avian influenza virus strains isolated from
341 migratory waterfowl in Mongolia on the way back from the southern Asia to their northern
342 territory. *Virology* **406**: 88-94.
- 343 34. Saitou, N. and Nei, M. 1987. The neighbor-joining method: a new method for
344 reconstructing phylogenetic trees. *Mol. Biol. Evol.* **4**: 406-425.
- 345 35. Sever, J. L. 1962. Application of a microtechnique to viral serological investigations. *J.*
346 *Immunol.* **88**: 320-329.

- 347 36. Stone, R. 2009. Swine flu outbreak. China first to vaccinate against novel H1N1 virus.
348 *Science* **325**: 1482-1483.
- 349 37. Xu, C., Fan, W., Wei, R. and Zhao, H. 2004. Isolation and identification of swine influenza
350 recombinant A/Swine/Shandong/1/2003(H9N2) virus. *Microbes. Infect.* **6**: 919-925.
- 351 38. Xu, K. M., Smith, G. J., Bahl, J., Duan, L., Tai, H., Vijaykrishna, D., Wang, J., Zhang, J. X.,
352 Li, K. S., Fan, X. H., Webster, R. G., Chen, H., Peiris, J. S. and Guan, Y. 2007. The genesis
353 and evolution of H9N2 influenza viruses in poultry from southern China, 2000 to 2005. *J.*
354 *Virology* **81**: 10389-10401.
- 355 39. Yamamoto, N., Sakoda, Y., Motoshima, M., Yoshino, F., Soda, K., Okamoto, M. and Kida,
356 H. 2011. Characterization of a non-pathogenic H5N1 influenza virus isolated from a
357 migratory duck flying from Siberia in Hokkaido, Japan, in October 2009. *Virology* **8**: 65.

358

359

360

361 **FIGURE LEGENDS**

362 Fig. 1. Phylogenetic tree of the HA genes of H9N2 influenza viruses. Nucleotides 163-1,048
363 (886 bases) of the HA genes were used for the analysis. Horizontal distances are proportional to
364 the minimum number of nucleotide differences required to join nodes and sequences. Numbers at
365 the nodes indicate confidence levels in a bootstrap analysis with 1,000 replicates. Viruses stocked
366 in our laboratory are highlighted in gray. Representative viruses in each sublineage are underlined.

367 Abbreviations: Sw, swine; Ck, chicken; SCk, silky chicken; Dk, duck; Osr, ostrich; Qa, quail; Ty,
368 turkey; HK, Hong Kong; Hb, Hebei; S.Af, South Africa; Hok, Hokkaido; Pak, Pakistan; and Wis,
369 Wisconsin.

370

371 Fig. 2. Changes in body weight in mice vaccinated once following challenge with HK/1073/99.
372 Five vaccinated mice of each group injected with HK/1073/99 vaccine (A), and with Dk/Hok/49/98
373 (B) were inoculated intranasally with HK/1073/99 and body weight was monitored for 14 days.
374 Data are shown as mean body weight changes in each group with corresponding standard deviation
375 (S.D.). Asterisks indicate that body weights were not significantly ($p<0.05$) decreased than PBS
376 injected group.

377

378 Fig. 3. Changes in body weight in mice vaccinated twice with Dk/Hok/49/98 vaccine following
379 challenge with HK/1073/99. Five mice from each Dk/Hok/49/98 vaccine group were inoculated
380 intranasally with HK/1073/99 and body weight was monitored for 14 days. Data are shown as
381 mean body weight changes in each group with corresponding S.D. Asterisks indicate that body
382 weights were not significantly ($p<0.05$) decreased than PBS injected group.

Table 1. H9N2 viruses used in this study

Sublineage	Virus	HA gene ^{a)}
Y280	A/chicken/Hebei/1/1996	AF536693
	A/duck/Hong Kong/Y280/1997	AF156376
	A/chicken/Hong Kong/G9/1997	AF156373
	A/duck/Hong Kong/W213/1998	AB432938
	A/swine/Hong Kong/10/1998	AF222811
	A/chicken/Hong Kong/FY20/1999	AF222611
	A/silkie chicken/Hong Kong/SF43/1999	AF186268
Korean	A/ostrich/South Africa/9508103/1995	AF218102
	A/duck/Hokkaido/31/1997	AB125927
	A/duck/Hokkaido/49/1998	AB125928
	A/duck/Hokkaido/9/1999	AB125929
	A/duck/Hokkaido/26/1999	AB125930
	A/duck/Hokkaido/13/2000	AB125931
	A/duck/Hokkaido/HY57/2005	AB455035
	A/duck/Mongolia/564/2003	AB538969 ^{b)}
	A/duck/Hokkaido/294/2006	AB538967 ^{b)}
	A/duck/Hokkaido/W299/2006	AB538968 ^{b)}
A/duck/Hokkaido/238/2008	AB485600 ^{b)}	
G1	A/quail/Hong Kong/G1/1997	AF156378
	A/Hong Kong/1073/1999	AJ404626
	A/chicken/Pakistan/2/1999	AJ291392
	A/quail/Hong Kong/A17/1999	AF222606
North American	A/turkey/Wisconsin/1/1966	D90305

^{a)} GenBank/EMBL/DDBJ Accession No.

^{b)} The HA gene sequence was submitted to the GenBank/EMBL/DDBJ databases in this study.

Table 2. The cross-reactivity of H9N2 viruses with antisera by HI test

Sublineage	Virus ^{b)}	Antisera ^{a)}						
		Y280			Korean		G1	North American
		Ck/HK/G9/97	Dk/HK/Y280/97	Dk/HK/W213/98	Dk/Hok/49/98	Dk/Hok/13/00	Qa/HK/G1/97	Ty/Wis/1/66
Y280	Ck/Hb/1/96	10,240	10,240	2,560	2,560	2,560	2,560	40
	Ck/HK/G9/97	<u>40,960</u>	10,240	2,560	1,280	2,560	2,560	40
	Dk/HK/Y280/97	20,480	<u>20,480</u>	2,560	2,560	2,560	5,120	320
	Sw/HK/10/98	2,560	10,240	640	640	1,280	1,280	40
	Dk/HK/W213/98	40,960	20,480	<u>2,560</u>	1,280	2,560	2,560	80
	Ck/HK/FY20/99	10,240	10,240	2,560	2,560	2,560	5,120	160
Korean	Dk/Hok/31/97	640	640	640	1,280	2,560	160	640
	Dk/Hok/49/98	320	320	160	<u>2,560</u>	2,560	160	640
	Dk/Hok/9/99	640	640	160	2,560	2,560	80	320
	Dk/Hok/26/99	320	640	160	2,560	2,560	40	640
	Dk/Hok/13/00	640	640	160	1,280	<u>2,560</u>	80	640
	Dk/Mon/564/03	320	320	160	1,280	2,560	160	320
	Dk/Hok/HY57/05	640	320	320	1,280	2,560	80	320
	Dk/Hok/W299/06	640	320	640	1,280	2,560	80	640
Dk/Hok/238/08	640	640	640	1,280	2,560	80	640	
G1	Qa/HK/G1/97	640	1,280	320	1,280	1,280	<u>5,120</u>	320
	Ck/Pak/2/99	1,280	1,280	640	640	640	640	80
	HK/1073/99	1,280	320	160	1,280	80	1,280	320
North American	Ty/Wis/1/66	80	20	20	320	320	<20	<u>640</u>

^{a)} Homologous reactions are underlined.

^{b)} This panel showed the representative strains of each sublineage.

Table 2 Nomura *et al.*

Table 3. Neutralizing antibody titers before challenge and virus titers of the lungs after challenge in mice vaccinated once

Vaccine	Dose of vaccine	NT titer to		Virus titer ^{a)} (logEID ₅₀ /g)
		HK/1073/99	Dk/Hok/49/98	
HK/1073/99	50 µg	320, 320, 160, 320, 640	ND	<1.5, <1.5, <1.5, <1.5, <1.5
	10 µg	80, 20, 80, 80, 40	ND	1.8, 3.7, 2.5, 2.3, 3.0
	2 µg	40, 20, 20, 20, 20	ND	4.7, 5.5, 5.5, 5.3, 6.0
	0.4 µg	<10, <10, <10, <10, <10	ND	5.7, 6.0, 5.0, 5.8, 5.5
	PBS	<10, <10, <10, <10, <10	ND	6.5, 6.2, 6.8, 6.5, 6.8
Dk/Hok/49/98	50 µg	40, 40, 40, 20, 40	160, 80, 80, 80, 80	4.3, 4.8, 4.5, 4.5, 4.8
	10 µg	<10, <10, <10, <10, <10	80, 80, 80, 80, 20	4.8, 5.0, 5.2, 4.7, 5.3
	2 µg	<10, <10, <10, <10, <10	<10, <10, <10, <10, <10	6.5, 5.8, 6.0, 6.3, 6.0
	0.4 µg	<10, <10, <10, <10, <10	<10, <10, <10, <10, <10	6.3, 5.8, 6.0, 6.5, 6.3
	PBS	<10, <10, <10, <10, <10	<10, <10, <10, <10, <10	6.2, 6.0, 6.5, 5.8, 6.5

Each of vaccine was injected intraperitoneally with 10 mice. Serum samples were collected 3 weeks after the vaccination.

Mice were challenged with 10^{6.0} EID₅₀ of HK/1073/99 intranasally.


^{a)} The lung samples were collected at 3 d.p.c. and virus titers were measured.



Table 4. Neutralizing antibody titers before challenge and virus titers of the lungs after challenge in mice vaccinated twice


Vaccine	Dose of vaccine	NT titer to		Virus titer ^{a)} (logEID ₅₀ /g)
		HK/1073/99	Dk/Hok/49/98	
Dk/Hok/49/98	50 µg	320, 320, 320, 160, 160	1,280, 640, 640, 320, 640	<1.5, <1.5, <1.5, <1.5, <1.5
	10 µg	40, <10, 20, 20, 40	320, 160, 320, 160, 160	2.0, 2.5, 2.0, 2.3, 2.5
	2 µg	<10, <10, <10, <10, <10	80, 160, 80, 80, 80	3.8, 3.5, 3.8, 3.5, 3.3
	0.4 µg	<10, <10, <10, <10, <10	<10, <10, <10, <10, <10	5.3, 5.8, 5.8, 6.0, 5.5
	PBS	<10, <10, <10, <10, <10	<10, <10, <10, <10, <10	5.8, 6.5, 6.0, 6.3, 5.8

Each of vaccine was injected intraperitoneally twice with 10 mice. Serum samples were collected 2 weeks after the second vaccination. Mice were challenged with 10^{6.0} EID₅₀ of HK/1073/99 intranasally.

^{a)} The lung samples were collected at 3 d.p.c. and virus titers were measured.







Characterization of avian influenza viruses isolated from domestic ducks in Vietnam in 2009 and 2010

Naoki Nomura · Yoshihiro Sakoda · Mayumi Endo · Hiromi Yoshida · Naoki Yamamoto · Masatoshi Okamatsu · Kenji Sakurai · Nam Van Hoang · Long Van Nguyen · Huy Duc Chu · Tien Ngoc Tien · Hiroshi Kida

Received: 23 June 2011 / Accepted: 15 October 2011 / Published online: 9 November 2011
© Springer-Verlag 2011

Abstract In the surveillance of avian influenza in Vietnam, 26 H9N2, 1 H3N2, 1 H3N8, 7 H4N6, 3 H11N3, and 1 H11N9 viruses were isolated from tracheal and cloacal swab samples of 300 domestic ducks in April 2009, and 1 H9N6 virus from 300 bird samples in March 2010. Out of the 27 H9 virus isolates, the hemagglutinins of 18 strains were genetically classified as belonging to the sublineage G1, and the other nine belonged to the Korean sublineage. Phylogenetic analysis revealed that one of the 27 H9 viruses was a reassortant in which the PB2 gene belonged to the Korean sublineage and the other seven genes belonged to the G1 sublineage. Three representative H9N2 viruses were intranasally inoculated into ducks, chickens, pigs, and mice. On the basis of experimental infection studies, it was found that each of the three viruses readily

infected pigs and replicated in their upper respiratory tracts, and they infected chickens with slight replication. Viruses were recovered from the lungs of mice inoculated with two of the three isolates. The present results reveal that H9 avian influenza viruses are prevailing and genetic reassortment occurs among domestic ducks in Vietnam. It is recommended that careful surveillance of swine influenza with H9 viruses should be performed to prepare for pandemic influenza.

Introduction

Avian influenza viruses of various subtypes are circulating in poultry in Asian countries [1, 15, 20, 30, 40]. In particular, H9N2 influenza virus is present in poultry in Eurasian countries [9–11, 25]. Since H9N2 viruses were isolated from quails in Hong Kong in 1988, they have become prevalent in live-bird markets and poultry farms in Asia [8, 34]. H9N2 virus infections have greatly affected not only the poultry industry but also public health [8, 40]. The hemagglutinin (HA) genes of Eurasian H9N2 viruses have been phylogenetically divided into G1, Y280, and Korean sublineages [10]. H9N2 viruses do not usually cause severe disease in poultry, but co-infection of H9N2 viruses with bacteria such as *Staphylococcus aureus*, *Haemophilus paragallinarum*, or attenuated coronavirus vaccine exacerbates the disease [12, 21]. H9N2 viruses were also isolated from domestic pigs in China [39] and Korea, and from humans with febrile respiratory illness in Hong Kong in 1998, 1999, 2003, 2008, and 2009 [4, 7, 23, 33, 43]. Thus, it is postulated that H9N2 virus may cause pandemic influenza in humans.

In our laboratory, avian influenza has been surveyed in Japan, Alaska, Siberia, Mongolia, and Australia since 1977

N. Nomura · Y. Sakoda · M. Endo · H. Yoshida · N. Yamamoto · M. Okamatsu · H. Kida (✉)
Laboratory of Microbiology, Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Kita 18 Nishi 9, Kita-ku, Sapporo 060-0818, Japan
e-mail: kida@vetmed.hokudai.ac.jp

K. Sakurai
OIE Regional Representation for Asia and the Pacific, Food Science Building 5F, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan

N. V. Hoang · L. V. Nguyen · H. D. Chu · T. N. Tien
Ministry of Agriculture and Rural Development, 15/78 Giaiphong, Phuongmai, Dongda, Hanoi, Vietnam

H. Kida
Research Center for Zoonosis Control, Hokkaido University, Kita 20 Nishi 10, Kita-ku, Sapporo 001-0020, Japan

H. Kida
Japan Science and Technology Agency Basic Research Programs, 4-1-8, Honcho Kawaguchi, Saitama 332-0012, Japan